{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihkq7z4z476dbwznbmghl5jt45ovhso5jf6nbwvwzuhijmqe4ttbu",
    "uri": "at://did:plc:o7x3aaueo7gbdj5s6ywwl7sl/app.bsky.feed.post/3mkzrufvsoqc2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreickf2e3dp652fimo3iygtw4ip4azg7w43nzwzys2xeu37xhebuvry"
    },
    "mimeType": "image/png",
    "size": 200508
  },
  "path": "/health-canada-kisunla-donanemab-approval/?utm_source=rss&utm_medium=rss&utm_campaign=health-canada-kisunla-donanemab-approval",
  "publishedAt": "2026-05-04T13:24:00.000Z",
  "site": "https://thedeepdive.ca",
  "tags": [
    "Healthcare",
    "Latest",
    "Alzheimer's",
    "Health Canada",
    "Health Canada Clears Second Alzheimer’s Disease Drug",
    "the deep dive"
  ],
  "textContent": "Health Canada has approved Eli Lilly’s once-monthly Alzheimer’s drug donanemab, giving Canada a second therapy that targets amyloid plaques tied to the disease. Eli Lilly Canada, part of Eli Lilly, said Health Canada authorized Kisunla, the brand name for donanemab, for adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease who are […]\n\nThe post Health Canada Clears Second Alzheimer’s Disease Drug appeared first on the deep dive.",
  "title": "Health Canada Clears Second Alzheimer’s Disease Drug"
}